Apellis(APLS)
搜索文档
Apellis(APLS) - 2021 Q2 - Earnings Call Transcript
2021-08-10 15:57
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations & Strategic Finance Cedric Francois - Co-Founder & Chief Executive Officer Federico Grossi - Chief Medical Officer Adam Townsend - Chief Commercial Officer Timothy Sullivan - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Umer Raffat - Evercore ISI Madhu Kumar - Goldman Sachs Ernie Rodriguez - Cowen ...
Apellis(APLS) - 2020 Q3 - Quarterly Report
2020-11-02 19:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or othe ...
Apellis(APLS) - 2020 Q2 - Quarterly Report
2020-07-31 06:41
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other jur ...
Apellis(APLS) - 2020 Q1 - Quarterly Report
2020-04-30 04:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other ju ...
Apellis(APLS) - 2019 Q4 - Annual Report
2020-02-28 05:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 | --- | --- | --- | |---------------------------------------------------------------------------------------------------------- ...